Healthy Aging Health Center
Obama's Health Plan: The Debate Goes On
Sept. 10, 2009 -- Declaring that ''the time for bickering is over,'' a passionate President Barack Obama took a forceful stand for health care reform Wednesday night, explaining his objectives for change while denouncing distortions made by opponents.
But was his speech a ''game changer"? Did it wipe out a month of slipping polls and town hall criticism of reform?
Health care reform is clouded in controversy and confusion. Get some clear answers here.
A single speech can't change the debate by itself, says Julius Hobson, a health policy adviser for the law firm Bryan Cave. "We're in a marathon that will run till Christmas.''
"I think he succeeded in delivering the message,'' Hobson says. "Did he succeed in changing the minds of the American people? Time will tell.''
It had been a rough August for supporters of the Democrats' initiatives. An AP-GfK survey released before the speech showed that public disapproval of Obama's handling of health care had jumped to 52%, an increase of 9 percentage points since July.
Clearly addressing the public as much as Congress, Obama touched on several areas of agreement on health reform, both past and present. "I am not the first president to take up this cause, but I am determined to be the last,'' he said.
He drew strong applause from the joint session of Congress when attacking insurance company discrimination against people with pre-existing medical conditions, citing a woman with breast cancer having her policy canceled because, he said, ''she forgot to declare a case of acne.''
''That is heartbreaking, it is wrong, and no one should be treated that way in the United States of America,'' Obama said.
Ending such insurance practices has gained broad political support, says E. Richard Brown, director of the UCLA Center for Health Policy Research.
The Public Option
On perhaps the most divisive issue of reform, though, Obama again backed a proposal for a ''public option,'' run like Medicare, to compete with private insurance companies in a health insurance exchange or marketplace. Republicans say the public option would eventually lead to the demise of private insurance.
But Obama also said he was receptive to other ideas to foster competition, such as a nonprofit co-op run by consumers. That openness to alternatives ''will disappoint many progressives,'' says Brown, a supporter of the public option.
Greg D'Angelo of the Heritage Foundation, which opposes a government-run public option, says if Obama had scrapped it, "people on the left would have revolted.''
The speech basically ''repackaged'' what Obama has already said on reform, D'Angelo says.
Still, the president reached out at times to Republicans, citing Sen. John McCain's idea to provide immediate insurance reform for helping people with pre-existing conditions.
He also said he would back changes of the medical malpractice insurance market, a topic that drove many Republicans to their feet in applause. Obama said he would pursue pilot projects on malpractice reform proposed by the Bush administration.
VIVELLE-DOT (estradiol transdermal system) IS AVAILABLE BY PRESCRIPTION ONLY.
INDICATION
Vivelle-Dot is used after menopause to: reduce moderate to severe hot flashes; treat moderate to severe dryness, itching and burning in or around the vagina; help reduce your chances of getting osteoporosis (thin weak bones); and treat certain conditions in which a young woman's ovaries do not produce enough estrogens naturally. Vivelle-Dot 0.025 mg/day is only used to prevent osteoporosis from menopause. If you use Vivelle-Dot only to treat your dryness, itching, and burning in and around your vagina or if you use Vivelle-Dot only to prevent osteoporosis from menopause, talk with your healthcare professional about whether a different treatment or medicine without estrogens might be better for you.
IMPORTANT SAFETY INFORMATION
Estrogens increase the chances of getting cancer of the uterus (womb). Report any unusual vaginal bleeding right away while you are taking estrogens. Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb).
Do not use estrogens with or without progestins to prevent heart disease, heart attacks, or strokes. Using estrogens with or without progestins may increase your chances of getting heart attacks, strokes, breast cancer, and blood clots. Using estrogens with progestins may increase your risk of dementia (decline in memory and thinking skills).
Vivelle-Dot should not be used if you have unusual vaginal bleeding; currently have or have had certain cancers, including cancer of the breast or uterus; had a stroke or heart attack in the recent past (for example, in the past year); currently have or have had blood clots; currently have or have had liver problems; or think you may be, or know that you are, pregnant.
The most common side effects that may occur with Vivelle-Dot are headache, breast tenderness, and back pain.
You and your healthcare professional should talk regularly about whether you still need treatment with Vivelle-Dot.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see Full Prescribing Information for Vivelle-Dot.

